Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management

被引:561
作者
Yeh, ETH [1 ]
Tong, AT [1 ]
Lenihan, DJ [1 ]
Yusuf, SW [1 ]
Swafford, J [1 ]
Champion, C [1 ]
Durand, JB [1 ]
Gibbs, H [1 ]
Zafarmand, AA [1 ]
Ewer, MS [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Unit 449, Houston, TX 77030 USA
关键词
cardiomyopathy; chemotherapy; complications; drugs;
D O I
10.1161/01.CIR.0000133187.74800.B9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors such as the molecular site of action, the immediate and cumulative dose, the method of administration, the presence of any underlying cardiac condition, and the demographics of the patient. Moreover, toxicity can be affected by current or previous treatment with other antineoplastic agents. Cardiotoxic effects can occur immediately during administration of the drug, or they may not manifest themselves until months or years after the patient has been treated. In this article we review commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity. Further research will be required to more accurately predict which patients are at risk for developing cardiotoxicity. In addition, management plans, as well as strategies to reduce cardiotoxicity, need to be developed.
引用
收藏
页码:3122 / 3131
页数:10
相关论文
共 110 条
[61]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[62]  
2-6
[63]   Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers [J].
Muggia, FM .
DRUGS, 1997, 54 (Suppl 4) :22-29
[64]  
Myers CE, 1988, ORGAN DIR TOXICITIES
[65]   Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody [J].
Needle, MN .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :55-60
[66]   Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer [J].
Nieto, Y ;
Cagnoni, PJ ;
Bearman, SI ;
Shpall, EJ ;
Matthes, S ;
Jones, RB .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (2A) :198-203
[67]   MYOCARDIAL TOXIC EFFECTS DURING RECOMBINANT INTERLEUKIN-2 THERAPY [J].
NORA, R ;
ABRAMS, JS ;
TAIT, NS ;
HIPONIA, DJ ;
SILVERMAN, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (01) :59-63
[68]  
Nousiainen T, 1999, EUR J HAEMATOL, V62, P135
[69]   Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma [J].
Olsen, E ;
Duvic, M ;
Frankel, A ;
Kim, Y ;
Martin, A ;
Vonderheid, E ;
Jegasothy, B ;
Wood, G ;
Gordon, M ;
Heald, P ;
Oseroff, A ;
Pinter-Brown, L ;
Bowen, G ;
Kuzel, T ;
Fivenson, D ;
Foss, F ;
Glode, M ;
Molina, A ;
Knobler, E ;
Stewart, S ;
Cooper, K ;
Stevens, S ;
Craig, F ;
Reuben, J ;
Bacha, P ;
Nichols, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :376-388
[70]  
ORZAN F, 1993, BRIT HEART J, V69, P496